The cardiovascular risk marker asymmetric dimethylarginine is elevated in asymptomatic, untreated HIV-1 infection and correlates with markers of immune activation and disease progression

Annals of Clinical Biochemistry

Volumn 51, Issue 5, 2014, Pages 568-575

  Hudson, Careen L ^a   Zemlin, Annalise E ^a   Ipp, Hayley ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Cardiovascular risk; endothelial dysfunction; HIV infection; inflammation

Indexed keywords

ADENOSINE DEAMINASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD3 ANTIGEN; CD38 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CREATININE; IMMUNOGLOBULIN G; INTERLEUKIN 6; N(G),N(G) DIMETHYLARGININE; ARGININE; IL6 PROTEIN, HUMAN; N,N-DIMETHYLARGININE;

ADAPTIVE IMMUNITY; ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; ASYMPTOMATIC INFECTION; B LYMPHOCYTE ACTIVATION; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; ETHNICITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE ACTIVATION; IMMUNOREGULATION; MAJOR CLINICAL STUDY; MALE; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROGNOSIS; SERUM; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VIRUS LOAD; ANALOGS AND DERIVATIVES; BLOOD; CARDIOVASCULAR DISEASES; CASE CONTROL STUDY; COMPLICATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY;

ADENOSINE DEAMINASE; ADULT; ARGININE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; CD8-POSITIVE T-LYMPHOCYTES; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-6; MALE; VIRAL LOAD;

EID: 84906346173     PISSN: 00045632     EISSN: 17581001     Source Type: Journal    
DOI: 10.1177/0004563213505848     Document Type: Article

References (45)

1. Triant VA,Lee H,Hadigan C, et al.Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease.J Clin Endocrinol Metab. 2007;92:2506-2512.
2. Dubé MP,Lipshultz SE,Fichtenbaum CJ, et al.Effects of HIV infection and antiretroviral therapy on the heart and vasculature.Circulation. 2008;118:e36-40.
3. Friis-Møller N,Weber R,Reiss P, et al.Cardiovascular risk factors in HIV patients - association with antiretroviral therapy results from the DAD study.AIDS. 2003;17:1179-1193.
4. Carr A,Samaras K,Thorisdottir A, et al.Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study.Lancet. 1999;353:2093-2099.
5. Grinspoon S,Carr A.Cardiovascular risk and body - fat abnormalities in HIV infected adults.N Engl J Med. 2005;352:48-62.
6. Ross R.Atherosclerosis - an inflammatory disease.N Engl J Med. 1999;340:115-126.
7. Ravani P,Tripepi G,Malberti F, et al.Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach.J Am Soc Nephrol. 2005;16:2449-2455.
8. Zoccali C,Bode-Böger SM,Mallamaci F, et al.Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study.Lancet. 2001;358:2113-2117.
9. Meinitzer A,Seelhorst U,Wellnitz B, et al.Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen risk and cardiovascular health study).Clin Chem. 2007;53:273-283.
10. Dückelmann C,Mittermayer F,Haider DG, et al.Asymmetric dimethylarginine enhances cardiovascular risk prediction in patients with chronic heart failure.Arterioscler Thromb Vasc Biol. 2007;27:2037-2042.
11. Lajer M,Tarnow L,Jorsal A, et al.Plasma concentration of asymmetric dimethylarginine predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy.Diabetes Care. 2008;31:747-752.
12. Krzyzanowska K,Mittermayer F,Wolzt M, et al.Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes.Diabetes Care. 2007;30:1834-1839.
13. Nijveldt RJ,Teerlink T,Van der Hoven B, et al.Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality.Clin Nutr. 2003;22:23-30.
14. Cooke JP,Dzau VJ.Nitric oxide synthase: role in the genesis of vascular disease.Annu Rev Med. 1997;48:489-509.
15. Blackwell S.The biochemistry, measurement and current clinical significance of asymmetric dimethylarginine.Ann Clin Biochem. 2010;47:17-28.
16. Ito A,Tsao PS,Adimoolam S, et al.Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase.Circulation. 1999;99:3092-3095.
17. Stu{double acute}linger MC,Tsao PS,Her JH, et al.Homocysteine impairs the nitric oxide synthase pathway.Role of asymmetric dimethylarginine. Circulation. 2001;104:2569-2575.
18. Lin KY,Ito A,Asagami T, et al.Impaired nitric oxide synthase pathway in diabetes mellitus. Role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase.Circulation. 2001;106:987-992.
19. Zhang WZ,Venardos K,Chin-Dusting J, et al.Adverse effects of cigarette smoke on NO availability. Role of arginine metabolism and oxidative stress.Hypertension. 2006;48:278-285.
20. Cooke JP.Asymmetrical dimethylarginine: the u{double acute}ber marker.Circulation. 2004;109:1813-1819.
21. Kurz K,Teerlink T,Sarcletti M, et al.Plasma concentrations of the cardiovascular risk factor asymmetric dimethylarginine (ADMA) are increased in patients with HIV-1 infection and correlate with immune activation markers.Pharmacol Res. 2009;60:508-514.
22. Jang JJ,Berkheimer SB,Merchant M, et al.Asymmetric dimethylarginine and coronary artery calcium scores are increased in patients infected with human immunodeficiency virus.Atherosclerosis. 2011;217:514-517.
23. Liu Z,Cumberland WG,Hultin LE, et al.Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression.J Acquir Immune Defic Syndr. 1997;16:83-92.
24. Antonioli L,Colucci R,La Motta C, et al.Adenosine deaminase in the modulation of immune system and its potential as a novel target for treatment of inflammatory disorders.Curr Drug Targets. 2012;13:842-862.
25. Casoli C,Lisa A,Magnani G, et al.Prognostic value of adenosine deaminase compared to other markers for progression to acquired immunodeficiency syndrome among intravenous drug users.J Med Virol. 1995;45:203-210.
26. De Milito A,Nilsson A,Titanji K, et al.Mechanisms of hypergammaglobulinemia and impaired antigen specific humoral immunity in HIV-1 infection.Blood. 2004;103:2180-2186.
27. Schulze F,Maas R,Freese R, et al.Determination of a reference value for NG, NG -dimethyl-L-arginine in 500 subjects.Euro J Clin Inv. 2005;35:622-626.
28. Lichtenstein KA,Armon C,Buchacz K, et al.Low CD4 T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study.Clin Infect Dis. 2010;51:435-447.
29. Triant VA,Regan S,Lee H, et al.Association of immunologic and virologic factors with myocardial infarction rates in a US Healthcare System.J Acquir Immune Defic Syndr. 2010;55:615-619.
30. Kaplan RC,Kingsley LA,Gange SJ, et al.Low CD4 T-cell count as a major atherosclerosis risk factor in HIV-infected women and men.AIDS. 2008;22:1615-1624.
31. Ho JE,Deeks SG,Hecht FM, et al.Initiation of antiretroviral therapy at higher nadir CD4 T-cell counts is associated with reduced arterial stiffness in HIV-infected individuals.AIDS. 2010;24:1897-1905.
32. Hsue P,Deeks SG,Hunt PW.Immunologic basis of cardiovascular disease in HIV-infected adults.J Infect Dis. 2012;205:S375-382.
33. Ipp H,Zemlin A.The paradox of the immune response in HIV infection: When inflammation becomes harmful.Clin Chim Acta. 2013;416:96-99.
34. Bofill M,Mocroft A,Lipman M, et al.Increased numbers of primed activated CD8+CD38+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients.AIDS. 1996;10:827-834.
35. Mahalingam M,Peakman M,Davies ET, et al.T cell activation and disease severity in HIV infection.Clin Exp Immunol. 1993;93:337-343.
36. Giorgi JV,Hultin LE,McKeating JA, et al.Shorter survival in advanced immunodeficiency virus type 1 infection is more closely associated with T-lymphocyte activation then with plasma virus burden or virus chemokine receptor usage.J Infect Dis. 1999;179:859-870.
37. Hsue PY,Hunt PW,Sinclair E, et al.Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses.AIDS. 2006;20:2275-2283.
38. Ford ES,Greenwald JH,Richterman AG, et al.Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection.AIDS. 2010;24:1509-1517.
39. Kaplan RC,Sinclair E,Landay AL, et al.T cell activation predicts carotid artery stiffness among HIV-infected women.Atherosclerosis. 2011;217:207-213.
40. Kaplan RC,Sinclair E,Landay AL, et al.T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women.J Infect Dis. 2011;203:452-463.
41. Lau B,Sharrett AR,Kingsley LA, et al.C-reactive protein is a marker for human immunodeficiency virus disease progression.Arch Intern Med. 2006;166:64-70.
42. Masia M,Bernal E,Padilla S, et al.The role of C-reactive protein as a marker for cardiovascular risk associated with antiretroviral therapy in HIV-infected patients.Atherosclerosis. 2007;195:167-171.
43. De Milito A.B lymphocyte dysfunctions in HIV infection.Curr HIV Res. 2004;2:11-21.
44. Ipp H,Zemlin AE,Glashoff RH, et al.Serum adenosine deaminase and total immunoglobulin G correlate with markers of immune activation and inversely with CD4 counts in asymptomatic, treatment-naive HIV infection.J Clin Immunol. 2013;33:605-612.
45. Baker JV,Neuhaus J,Duprez D, et al.HIV replication, inflammation and the effect of starting antiretroviral therapy on plasma assymetric dimethylarginine, a novel marker of endothelial dysfunction.J Acquir Immune Defic Syndr. 2012;60:128-134.